Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics

QR Code

Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics

© 2017 Springer International Publishing AG A major advancement in therapy of type 1 diabetes mellitus (T1DM) is the discovery of new treatment which avoids and even replaces the absolute requirement for injected insulin. The need for multiple drug therapy of comorbidities associated with T1DM incre...

Full description

Bibliographic Details
Main Authors:	Mikov, M., Ðanic, M., Pavlovic, N., Stanimirov, B., Golocorbin-Kon, S., Stankov, K., Al-Salami, Hani
Format:	Journal Article
Published:	Springer France 2017
Online Access:	http://hdl.handle.net/20.500.11937/58252

Similar Items

Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats
by: Al-Salami, Hani, et al.
Published: (2012)

Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
by: Danic, M., et al.
Published: (2018)

Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles
by: Pavlovic, N., et al.
Published: (2018)

Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics
by: Al-Salami, Hani, et al.
Published: (2008)

Bile acids and probiotics could help treating diabetes
by: Calasan, J., et al.
Published: (2012)

The applications of microencapsulated formulation of gliclazide and bile acids in Type-1 diabetes mellitus
by: Mathavan, Sangeetha
Published: (2017)

Application of bile acids in drug formulation and delivery
by: Stojancevic, M., et al.
Published: (2014)

THE EFFECT OF BILE ACID SALT SODIUM 3ALPHA, 7ALPHA-DIHYDROXY-12-KETO-5BETA-CHOLANATE (MKC) AND PROBIOTIC PRETREATMENT ON GLICLAZIDE PERMEATION IN ILEAL TISSUES FROM HEALTHY AND DIABETIC RATS
by: Mikov, M., et al.
Published: (2014)

High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect
by: Golocorbin-Kon, S., et al.
Published: (2017)

The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes
by: Mikov, M., et al.
Published: (2017)

Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats
by: Al-Salami, Hani, et al.
Published: (2009)

Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
by: Mooranian, Armin, et al.
Published: (2014)

Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats
by: Al-Salami, Hani, et al.
Published: (2008)

The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus
by: Woodhams, L., et al.
Published: (2017)

The influence of bile salts on the distribution of simvastatin in the octanol/buffer system
by: Đanić, M., et al.
Published: (2016)

Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects
by: Mathavan, S., et al.
Published: (2017)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment
by: Mooranian, Armin, et al.
Published: (2015)

Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid
by: Mathavan, S., et al.
Published: (2018)

Probiotics applications in autoimmune diseases
by: Al-Salami, Hani, et al.
Published: (2012)

Correlation between in vitro tests for blood brain barrier penetration with in vivo gliclazide penetration
by: Lalic-Popovic, M., et al.
Published: (2013)

Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat
by: Lalic-Popovic, M., et al.
Published: (2013)

The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes
by: Mathavan, S., et al.
Published: (2015)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment (vol 32, pg 151, 2014)
by: Mooranian, A., et al.
Published: (2015)

A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes
by: Mathavan, Sangeetha, et al.
Published: (2015)

An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations
by: Mooranian, A., et al.
Published: (2015)

Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid
by: Mooranian, A., et al.
Published: (2018)

Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes
by: Mooranian, Armin, et al.
Published: (2018)

Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System
by: Negrulj, Rebecca, et al.
Published: (2013)

A review on the formulation and analysis of anti-diabetic agent: Gliclazide
by: Helal Uddin, A.B.M., et al.
Published: (2013)

Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics
by: Mooranian, Armin, et al.
Published: (2014)

Pharmacokinetic and Drug Absorption Profiles of the Anti-Hyperglycaemic Agent Gliclazide in Oral Tissue-Targeted Microcapsules in Rats
by: Jovic, Jelena, et al.
Published: (2020)

Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes
by: Negrulj, R., et al.
Published: (2015)

The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders
by: Stepanov, V., et al.
Published: (2013)

Novel artificial cell microencapsulation of probucol and bile acids in diabetes mellitus
by: Mooranian, Armin
Published: (2018)

Advanced bile acid-based multi-compartmental microencapsulated pancreatic ß-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.
by: Mooranian, A., et al.
Published: (2014)

The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes
by: Mooranian, Armin, et al.
Published: (2016)

Effect of multistrain probiotic supplementation in individuals with type 2 diabetes mellitus
by: Firouzi, Somayyeh
Published: (2015)

Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women
by: Lalic-Popovic, M., et al.
Published: (2013)

Decreased placental and transcellular permeation of cefuroxime in pregnant women with diabetes
by: Lalic-Popovic, M., et al.
Published: (2015)

The Effect of Diabetes and Hypertension on the Placental Permeation of the Hydrophilic Drug, Ranitidine
by: Lalic-Popovic, M., et al.
Published: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r6ua9bp9jsdvjd430jvj4u957u